Tomoki Yoneyama
Tomoki Yoneyama has a total of 54 co-authors. Here are the top co-authors by number of shared publications:
- Adnan O. Abu-Yousif
Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
65 shared publications - Alexander Parent
11Research and Development, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts
65 shared publications - Angel E. Maldonado Lopez
Oncology Drug Discovery Unit, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts
65 shared publications - Angelo Porciuncula
Department of Pathology, Yale University School of Medicine, New Haven, Connecticut
65 shared publications - Atsushi Matsuda
Oncology Drug Discovery Unit, Takeda Development Center Americas, Inc. (TDCA), Lexington, Massachusetts
65 shared publications - Camilla L. Christensen
Oncology Precision and Translational Medicine, Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts
65 shared publications
Latest Publications
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 10 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Antibodies Used in Macrophage/Dendritic Cell Panel
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 10 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Antibodies Used in Macrophage/Dendritic Cell Panel
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 13 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Evaluation of CCR2 expression levels and the impact of TAK-500 treatment on T and NK cell activation and cytokine production in vitro.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 13 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Evaluation of CCR2 expression levels and the impact of TAK-500 treatment on T and NK cell activation and cytokine production in vitro.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 12 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Complete loss of receptor-mediated TAK-500 and mTAK-500 activity observed on human and murine peripheral blood monocytes lacking cell surface CCR2 expression
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 12 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Complete loss of receptor-mediated TAK-500 and mTAK-500 activity observed on human and murine peripheral blood monocytes lacking cell surface CCR2 expression
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 14 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Clinicopathologic characteristics of NSCLC, CRC and PDAC cohorts
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 14 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Clinicopathologic characteristics of NSCLC, CRC and PDAC cohorts
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 3 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Antibodies Used in Murine Receptor Occupancy Flow Panel
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 3 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Antibodies Used in Murine Receptor Occupancy Flow Panel
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 6 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Gating Strategy for Evaluating CCR2 in Dissociated Tumor Cells: T Cell Panel
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 6 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Gating Strategy for Evaluating CCR2 in Dissociated Tumor Cells: T Cell Panel
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table 4 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Antibodies Used in Human Receptor Occupancy Flow Panel
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table 4 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Antibodies Used in Human Receptor Occupancy Flow Panel
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 10 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Gating Strategy for Murine Macrophage/Dendritic Cell Panel
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 10 from Selective STING Activation in Intratumoral Myeloid Cells via CCR2-Directed Antibody–Drug Conjugate TAK-500
Gating Strategy for Murine Macrophage/Dendritic Cell Panel